Bio-Rad Laboratories, Inc. (BIO) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Bio-Rad Laboratories financial statements at a glance

Bio-Rad Laboratories reported revenue of $2.58 billion for fiscal year 2025 (ended December 31, 2025), up 0.7% from fiscal year 2024. Net income was $759.90 million, a net margin of 29.4%, and diluted earnings per share were $27.85.

At the end of fiscal year 2025 it had total assets of $10.58 billion, total liabilities of $3.12 billion and shareholders' equity of $7.45 billion, with cash and short-term investments of $1.54 billion and total debt of $1.39 billion.

Its operations brought in $532.20 million of cash; capital spending was $157.60 million, leaving free cash flow of $374.60 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

BIO logo

Bio-Rad Laboratories, Inc.

BIOUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
2.58B
Prev Year: 2.57B
YoY: +0.7%
Operating Revenue
2.58B
Prev Year: 2.57B
YoY: +0.7%
Total Unusual Items Excluding Goodwill
729.20M
Prev Year: -2.65B
YoY: +127.6%
Total Unusual Items
729.20M
Prev Year: -2.65B
YoY: +127.6%
Normalized EBITDA
480.70M
Prev Year: 504.20M
YoY: -4.7%
Tax Rate for Calcs
0.237
Prev Year: 0
Tax Effect of Unusual Items
172.58M
Prev Year: -563.64M
YoY: +130.6%
Interest Income
95.50M
Prev Year: 82.00M
YoY: +16.5%
Write-offs
6.00M
Impairment of Capital Assets
172.80M
Gain on Sale of Securities
908.00M
Prev Year: -2.65B
YoY: +134.3%
Non-operating Interest Income
95.50M
Prev Year: 82.00M
YoY: +16.5%
Provision for Doubtful Accounts
1.40M
Cost of Revenue
1.24B
Prev Year: 1.19B
YoY: +4.7%
Gross Profit
1.34B
Prev Year: 1.38B
YoY: -2.8%
Operating Expense
1.12B
Prev Year: 1.11B
YoY: +1.0%
Selling General and Administrative
844.30M
Prev Year: 814.00M
YoY: +3.7%
Research and Development
275.60M
Prev Year: 295.90M
YoY: -6.9%
Operating Income
218.60M
Prev Year: 269.00M
YoY: -18.7%
Net Non Operating Interest Income Expense
46.50M
Prev Year: 33.10M
YoY: +40.5%
Non-operating Interest Expense
49.00M
Prev Year: 48.90M
YoY: +0.2%
Other Income Expense
730.40M
Prev Year: -2.64B
YoY: +127.6%
Special Income Charges
-178.80M
Other Non-operating Income (expense)
1.20M
Prev Year: 1.60M
YoY: -25.0%
Pre-tax Income
995.50M
Prev Year: -2.34B
YoY: +142.5%
Provision for Income Taxes
235.60M
Prev Year: -498.30M
YoY: +147.3%
Net Income Common Stockholders
759.90M
Prev Year: -1.84B
YoY: +141.2%
Net Income
759.90M
Prev Year: -1.84B
YoY: +141.2%
Net Income Including Non-Controlling Interests
759.90M
Prev Year: -1.84B
YoY: +141.2%
Net Income from Continuing Operations
759.90M
Prev Year: -1.84B
YoY: +141.2%
Diluted NI Available to Com Stockholders
759.90M
Prev Year: -1.84B
YoY: +141.2%
Basic EPS
27.87
Prev Year: -65.36
YoY: +142.6%
Diluted EPS
27.85
Prev Year: -65.36
YoY: +142.6%
Weighted Average Shares (basic)
27.26M
Prev Year: 28.21M
YoY: -3.4%
Weighted Average Shares (diluted)
27.28M
Prev Year: 28.21M
YoY: -3.3%
Total Operating Income as Reported
47.20M
Prev Year: 269.00M
YoY: -82.5%
Total Expenses
2.36B
Prev Year: 2.30B
YoY: +2.9%
Net Income from Continuing and Discontinued Operation
759.90M
Prev Year: -1.84B
YoY: +141.2%
Normalized Income
203.28M
Prev Year: 238.36M
YoY: -14.7%
Interest Expense
49.00M
Prev Year: 48.90M
YoY: +0.2%
Net Interest Income
46.50M
Prev Year: 33.10M
YoY: +40.5%
EBIT
1.04B
Prev Year: -2.29B
YoY: +145.5%
EBITDA
1.21B
Prev Year: -2.14B
YoY: +156.5%
Reconciled Cost of Revenue
1.24B
Prev Year: 1.19B
YoY: +4.7%
Reconciled Depreciation
165.40M
Prev Year: 151.60M
YoY: +9.1%
Net Income from Continuing Operation Net Minority Interest
759.90M
Prev Year: -1.84B
YoY: +141.2%
Values in USD

Bio-Rad Laboratories key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$2.6B$2.6B$2.7B$2.8B$2.9B
Gross profit$1.3B$1.4B$1.4B$1.6B$1.6B
Operating income$218.6M$269.0M$337.8M$475.1M$500.3M
Net income$759.9M-$1.8B-$637.3M-$3.6B$4.3B
Diluted EPS$27.85-$65.36-$21.82-$121.79$140.56
Total assets$10.6B$9.4B$12.3B$13.5B$17.8B
Total liabilities$3.1B$2.8B$3.6B$3.9B$4.1B
Shareholders' equity$7.5B$6.6B$8.7B$9.6B$13.7B
Cash and short-term investments$1.5B$1.7B$1.6B$1.8B$869.9M
Total debt$1.4B$1.4B$1.4B$1.4B$223.4M
Operating cash flow$532.2M$455.2M$374.9M$194.4M$669.5M
Capital spending$157.6M$189.0M$156.7M$114.3M$133.7M
Free cash flow$374.6M$266.2M$218.2M$80.1M$535.7M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Bio-Rad Laboratories's revenue in fiscal year 2025?

$2.58 billion, up 0.7% from $2.57 billion in fiscal year 2024.

How much profit does Bio-Rad Laboratories make?

Bio-Rad Laboratories reported net income of $759.90 million for fiscal year 2025 (29.4% of revenue); operating income was $218.60 million.

How much cash and debt does Bio-Rad Laboratories have?

At the end of fiscal year 2025: cash and short-term investments of $1.54 billion and total debt of $1.39 billion.

What is Bio-Rad Laboratories's free cash flow?

$374.60 million in fiscal year 2025 (operating cash flow of $532.20 million minus capital spending of $157.60 million).

MoreBio-Rad Laboratories stock overviewBio-Rad Laboratories executive teamBio-Rad Laboratories shareholdersBio-Rad Laboratories revenue by segment
RelatedAnalytical Laboratory Instrument Manufacturing industryManufacturing sectorQuidelOrtho (QDEL)Exagen (XGN)Global Cord Blood (CORBF)Biomerica (BMRA)QHSLab (USAQ)Trinity Biotech (TRIB)
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
© 2026 DataPorium. All rights reserved.|About & MethodologyPrivacy PolicyTerms of Use
LinkedInLinkedInXXYouTubeYouTube